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Lymphadenectomyedure has been introduced in vulvar cancer treatment to reduce morbidity and
thereby improve quality of life. Aim of this study was to compare quality of life in vulvar cancer patients who
were treated with a SLN-procedure only to those who underwent inguinofemoral lymphadenectomy.
Moreover, it was evaluated what patients would advise relatives on the application of the SLN-procedure in
light of possible false negative results.
Methods. Patients who participated in the GROningen INternational Study on Sentinel nodes in Vulvar
cancer (GROINSS-V) were invited to ﬁll out three questionnaires: the EORTC QLQ-C30, a vulvar speciﬁc
questionnaire and a questionnaire about the opinion of patients on new treatment options. Patients who only
underwent SLN-procedure were compared to those who subsequently underwent inguinofemoral
lymphadenectomy because of a positive SLN.
Results. With a response rate of 85%, 35 patients after the SLN-procedure and 27 patients after
inguinofemoral lymphadenectomy ﬁlled out the questionnaires. No difference in overall quality of life was
observed between the two groups. The major difference was the increase in complaints of lymphedema of
the legs after inguinofemoral lymphadenectomy. The majority of patients would advise the SLN-procedure to
relatives. Patients after inguinofemoral lymphadenectomy were more reserved concerning the acceptable
false negative rate of a new diagnostic procedure.
Conclusions. Patients who underwent the SLN-procedure report less treatment related morbidity
compared to those who underwent inguinofemoral lymphadenectomy. However, this did not inﬂuence
overall quality of life. Furthermore, patients who underwent inguinofemoral lymphadenectomy are more
reserved in advising the SLN-procedure to relatives.
© 2008 Elsevier Inc. All rights reserved.IntroductionThe aim of modern vulvar cancer treatment is to minimize
treatment related morbidity, without compromising survival rates.
The most important prognostic factor in patients with vulvar cancer is
the inguinofemoral lymph node status [1]. Until recently inguinofe-
moral lymphadenectomy was the only possibility to be adequately
informed on the lymph node status. However, the morbidity of this
procedure is high, while only 25–35% of early stage vulvar cancer
patients will have lymph node metastases and thereby beneﬁt from
this surgery [1,2]. In the other 65–75% this intervention will (in
retrospect) probably be only diagnostic. In order to reduce morbidity
the sentinel lymph node (SLN) procedure was introduced in vulvaran der Zee).
ll rights reserved.cancer treatment with promising results in different accuracy-studies
[3–10]. Its safety has recently been shown in the Groningen
International Study on Sentinel Nodes in Vulvar cancer (GROINSS-V)
with a false negative rate of 2.8% in patients with unifocal early stage
disease [11]. Frequently occurring sequelae of inguinofemoral lym-
phadenectomy are lymphedema, painful legs and recurrent erysipelas.
Hence, this procedure will interfere with quality of life. The GROINSS-
V showed that both short-term as well as long-term morbidity were
signiﬁcantly decreased in patients who only underwent the SLN
procedure compared to those who also underwent subsequent
inguinofemoral lymphadenectomy. For lymphedema the percentages
were 1.9% vs. 25.2% respectively and for recurrent erysipelas 0.4% vs.
16.2% [11]. Our hypothesis was that patients after a SLN procedure
only might have a better quality of life due to less long-term
morbidity. In GROINSS-V however assessment of quality of life was
not part of the protocol and until now no comparable studies have
been performed in vulvar cancer.
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acceptable false-negative rates for the SLN procedure in vulvar cancer.
Patients, who themselves had undergone a vulvectomy and inguino-
femoral lymphadenectomy, were asked what they would recommend
a friend or sister with vulvar cancer: a new technique (the SLN
procedure) or the standard therapy (inguinofemoral lymphadenect-
omy). Remarkably, most patients would not recommend the SLN
procedure, although they had experienced themselves severe com-
plications and side effects of the radical treatment they had under-
gone [12].
Aims of the present study were 1) to compare quality of life in
patients with vulvar cancer who were treated by the SLN procedure
only with those who underwent inguinofemoral lymphadenectomy
and 2) to evaluate what these patients would advise their relatives on




Patients who participated in GROINSS-V between March 2000 and
December 2005 and who were treated in either University Medical
Center Groningen, Radboud University Nijmegen Medical Center or
Erasmus University Medical Center Rotterdam were eligible for the
study. All eligible patients with a positive SLN treated in the
participating centers during this time period were invited to ﬁll out
the questionnaires, while an equal number of patients with a negative
SLN were age-matched to the eligible patients with a positive SLN.
Patients with recurrent disease or with a second malignancy were
excluded. No patients with a false negative SLN were included. Also
patients who had radiotherapy on the groins instead of an inguino-
femoral lymphadenectomy or those who refused inguinofemoral
lymphadenectomy in case of a positive SLN were excluded. The
questionnaires were sent by mail accompanied by a return envelope
and a guidance letter onwhich a telephone number was noted in case
help was needed to answer the questions. No reminders were sent.
The surgical procedure has been described in detail previously [11]. In
short, the SLN procedurewas performedwith the combined technique
(radioactive tracer and blue dye). When the SLN was negative, no
further treatment followed. If metastatic disease was identiﬁed in the
SLN, an inguinofemoral lymphadenectomy was performed, either
during the same operation when found positive by frozen sectioning
or during a subsequent procedure if the SLN was found positive at
routine pathologic examination or ultrastaging. When more than one
intranodal metastasis and/or extranodal growth was detected, post-
operative external beam radiotherapy (50 Gy) to the groin/pelvis was
recommended. Patients were seen every 2 months at the outpatients'
clinic for the ﬁrst 2 years after primary treatment, and subsequently
biannually.
Questionnaires
The questionnaire consisted of three different lists; the European
Organization for Research and Treatment of Cancer Quality of Life
Questionnaire C30 (EORTC QLQ-C30), the vulva speciﬁc questionnaire
(VSQ) and the patients' opinion questionnaire.
The EORTC QLQ-C30 version 3.0, a cancer-speciﬁc questionnaire, is
composed of ﬁve functional scales (physical, role, emotional,
cognitive, social), the global health status and nine symptom scales
(fatigue, nausea and vomiting, pain, dyspnoea, insomnia, appetite
loss, constipation, diarrhea, ﬁnancial difﬁculties). The global health
status correlates signiﬁcantly with all the functional and symptom
scales [13]. For the functional and global quality of life (QOL) scales a
higher score indicates a better level of functioning, for the symptom
scales a higher score indicates a worse level of functioning. At present,vulva speciﬁc questionnaires translated into Dutch language are not
available. We used a questionnaire based on an existing vulva speciﬁc
questionnaire in English language (Functional Assessment of Cancer
Therapy-Vulvar; FACT-V) [14]. The questionnaire consists of four
symptom scales (vulva speciﬁc symptoms, sexual functioning, edema,
and urinating discomfort) and ﬁve functional scales (sexual function-
ing, physical functioning, body image, future perspective and
contentment with procedure). The questionnaire consisted of 17
questions, and answering was according to what the patients
experienced the last 7 days. Scale reliability was determined using
Cronbach's alpha coefﬁcients, values above 0.70 were considered
adequate. The internal consistencies of the subscale data in the EORTC
QLQ-C30, evaluated by Cronbach's alpha coefﬁcients were 0.79 for
physical functioning, 0.85 for role functioning, 0.87 for emotional
functioning, 0.59 for cognitive functioning, 0.89 for social functioning,
0.89 for fatigue, 0.47 for nausea and vomiting, 0.84 for pain and 0.92
for global health status. Cronbach's alpha for the whole questionnaire
was 0.87. For the vulvar speciﬁc questionnaire they were 0.52 for
physical functioning, 0.81 for sexual functioning, 0.58 for vulvar
symptoms, 0.57 for edema and−0.09 for urination. Cronbach's alpha
for the whole questionnaire was 0.65. The scales with a Cronbach's
alpha below 0.70 were also analyzed per item.
In the patients' opinion questionnaire patients were asked what
they would recommend a friend or family member with vulvar
cancer: the standard therapy (inguinofemoral lymphadenectomy)
with the accompanying side effects or the new technique (SLN
procedure) with a chance of missing a metastasis being respectively
10 out of 100, 1 out of 100 or 1 out of 1000. The patients' opinion
questionnaire is a non-validated questionnaire that was also used in a
previous study from our group [12].
Statistical analysis
All data were analyzed with the Statistical Package for the Social
Sciences (SPSS 14). For the quality of life questionnaire, including the
vulva speciﬁc part, data were analyzed in accordance with the EORTC
QLQ-C30 scoring manual [15]. In case of missing values, a scale was
scored only if more than half of the items in this scale were answered,
and the mean of all items in the concerning scale for that patient was
used to score missing items. Patient characteristics between the two
surgical groups were compared by using chi-square tests in case of
categorical data and the T-test in case of continuous data. Due to
skewness of data, the Mann Whitney U-test was used to compare




Questionnaireswere sent to 37 eligible patients with a positive SLN
and 37 age-matched patients with a negative SLN. Sixty-two of 74
patients (84%) returned the questionnaires. The mean age was
69 years (SD 13). Thirty-ﬁve patients (56.5%) had a negative SLN
and 27 patients (43.5%) had a positive SLN. In all patients with a
positive SLN a uni-or bilateral inguinofemoral lymphadenectomy was
performed. Postoperative radiotherapy to the groins was given in 10/
27 (37%) of the patients with a positive SLN. Patients' clinical
characteristics are summarized in Table 1. The median follow-up
between surgery and the questionnaire was 33 months (interquartile
range: 20–48).
EORTC QLQ-C30
Overall, there was no difference in quality of life between patients
who underwent SLN procedure alone and those who underwent an
Table 3
Results of 62 vulvar cancer patients answering the Vulva Speciﬁc Questionnaire: SLN
procedure (n=35) versus inguinofemoral lymphadenectomy (IFLA) (n=27).
SLN mean (SD) IFLA mean (SD) p-value
Functional scalesa
Physical functioning 85 (17) 80 (18) 0.27
Discomfort groins/vulva/legs 86 (20) 69 (32) 0.03
Discomfort sitting 87 (18) 86 (28) 0.46
Discomfort bending 83 (27) 85 (20) 0.83
Sexual functioningb 78 (19) 81 (26) 0.67
Future perspective 70 (27) 64 (28) 0.41
Body image 43 (35) 59 (33) 0.09
Contentment 90 (27) 78 (31) 0.04⁎
Sexual activeness 6 (21) 13 (21) 0.06
Symptom scalesc
Vulvar symptoms 14 (14) 10 (12) 0.33
Discharge/blood loss 5 (12) 1 (6) 0.17
Fetor 7 (16) 5 (12) 0.77
Itching 24 (26) 16 (19) 0.29
Pain/numbness 22 (28) 20 (27) 0.76
Edema 12 (22) 35 (32) 0.001⁎
Complaints 12 (24) 27 (29) 0.01⁎
Stockings 12 (30) 43 (46) 0.003⁎
Urination 14 (18) 18 (18) 0.30
Incontinence 18 (30) 26 (34) 0.32
Discomfort 10 (21) 10 (18) 0.68
a A higher score indicates a higher/better level of functioning/contentment.
b Questions on sexual functioning were only answered by womenwho were sexually
active.
c A higher score indicates a high level of symptomatology/problems.
⁎ p b 0.05
Table 1
Patients characteristics.
Total (n=62) SLN (n=35) CLA (N=27) Test p-value
Age (years)
Mean 70 (±13) 71 (±14) 68 (±12) T-test 0.30
Site of groin surgery (%)
One groin 30 (48%) 16 (46%) 14 (52%) χ2 0.63
Both groins 32 (52%) 19 (54%) 13 (48%)
Vulvar therapy (%)
Wide local excision 58 (93.5%) 32 (91%) 26 (96%) χ2 0.63
Radical vulvectomy 1 (1.5%) 1 (3%) 0 (0%)
Radiotherapy 3 (5%) 2 (6%) 1 (4%)
Tumor diameter (mm)
Mean 23 (±11) 23 (±11) 25 (±10) T-test 0.44
T1 27 (47%) 17 (49%) 10 (37%) χ2 0.36
T2 35 (53%) 18 (51%) 17 (63%)
Depth of invasion (mm)
Mean 5.4 (±3.6) 5.5 (±4.1) 5.3 (±2.9) T-test 0.83
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reported more often by patients who underwent inguinofemoral
lymphadenectomy (p=0.01). The quality of life-scores are shown in
Table 2. To investigatewhether quality of lifewas inﬂuenced by agewe
compared patients below the age of 69 with those older than 69 years
(mean age): better physical functioning (p=0.001) as well as better
role functioning (p=0.004) was experienced by the patients below
the age of 69. Nausea and appetite loss were more frequently
experienced in the older patients (p=0.027 and 0.008 respectively).
Other scales did not differ between these two age groups.
Vulvar speciﬁc questionnaire
Patients who underwent inguinofemoral lymphadenectomy
reported more discomfort in groins, vulva and legs (p=0.03).
Complaints of lymphedema (p=0.01) and the need to wear stockingsTable 2
Results of 62 vulvar cancer patients answering the QLQ-C30 questionnaire: SLN
procedure (n=35) versus inguinofemoral lymphadenectomy (IFLA) (n=27).




80 (18) 80 (23) 0.62
Functional scalesa
Physical functioning 84 (21) 80 (19) 0.43
Role functioning 87 (22) 85 (26) 0.87
Emotional functioning 90 (14) 89 (19) 0.63
Cognitive functioning 94 (11) 94 (14) 0.90
Concentration 95 (12) 96 (14) 0.44
Memory 92 (16) 91 (18) 0.83
Social functioning 96 (13) 90 (22) 0.23
Symptom scalesb
Fatigue 23 (22) 18 (24) 0.23
Nausea and vomiting 3 (11) 2 (10) 0.61
Nausea 6 (19) 4 (14) 0.61
Vomiting 1 (6) 1 (6) 0.85
Pain 15 (21) 14 (24) 0.63
Dyspnoea 12 (24) 12 (21) 0.79
Insomnia 14 (25) 23 (29) 0.15
Appetite loss 10 (24) 9 (22) 0.65
Constipation 7 (16) 5 (15) 0.53
Diarrhea 9 (20) 2 (13) 0.11
Financial difﬁculties 2 (11) 12 (25) 0.01⁎
a A high score on a functional scale represents a high/healthy level of functioning.
b A high score on a symptom scale represents a high level of symptomatology/
problems.
⁎ pb0.05.(p=0.003) were more often reported by the patients treated with an
inguinofemoral lymphadenectomy (Table 3). Patients after the SLN
procedure only were more content with the treatment they had
undergone (p=0.04). Other functional and symptom scales did not
show statistically signiﬁcant differences. Only 11/62 patients (17.7%)
were sexually active, of whom seven only sporadically. The women
who had regular sexual intercourse were signiﬁcantly younger
compared to those with sporadically sexual intercourse and those
with no sexual intercourse (mean age 43, 68 and 72 years respectively,
pb0.0001). No differences in sexual activeness were observed
between SLN procedure and inguinofemoral lymphadenectomy. The
questions on sexual functioning were only answered by women who
were sexually active. Only two patients reported regular complaints
with sexual intercourse, both underwent inguinofemoral lymphade-
nectomy. The other patients reported no or little complaints.
Patients' opinion questionnaire
The questions on what patients would recommend their relatives
revealed that patients after inguinofemoral lymphadenectomy were
more reserved concerning the acceptable false negative rate of a
new treatment compared to patients who had a negative sentinel
lymph node. When the SLN procedure would have a false negative
rate of 10%, 48% of the patients who underwent inguinofemoral
lymphadenectomy and 84% of the patients who underwent a SLN
procedure only would recommend it to relatives. These differences
were also observed with a suggested false negative rate of 1% and
0.1% (Table 4).Table 4
Maximum false negative rate of the SLN procedure acceptable to patients (n=62).
Maximum acceptable
false-negative rate







10% 69% 84% 48% p=0.005
1% 82% 97% 62% p=0.001
0.1% 87% 97% 71% p=0.013
⁎ Tested with chi-square.
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Our study shows that patients who have been treated for vulvar
cancer and underwent an inguinofemoral lymphadenectomy experi-
ence more often long-term symptoms of lymphedema and discomfort
of groins and legs compared to those who only had SLN removal. Also,
they are less content with the operative procedure they underwent.
On the other, more global quality of life scales (except for ﬁnancial
difﬁculties, for which we have no clear explanation), no differences
were observed between the two groups. A comparable quality of life
study comparing these two vulvar cancer patient groups was never
performed until now.
Our present study does not support our original idea that a
decrease in especially long-term morbidity also translates into an
improved overall quality of life for vulvar cancer patients. Several
reasons for not ﬁnding an improvement in quality of life can be
envisioned. An important limitation of our study is the small study
population, which unfortunately is often the case in vulvar cancer
studies, due to the rareness of this disease. Two studies in breast
cancer also reported that the type of axillary surgery (SLN procedure
or axillary lymph node dissection) did not seem to affect global
quality of life, although axillary lymph node dissectionwas associated
with worse arm/shoulder mobility, more pain and more sensory
morbidity [16,17]. Both were relatively small studies (n=56 and
n=115, respectively). A recent prospective study in 829 breast cancer
patients by Fleissig et al in contrast showed that quality of life was
better after SLN procedure compared to axillary lymph node
dissection [18]. In another prospective study by Rietman et al.
(n=181) it was also shown that 2 years after surgery, breast cancer
patients who underwent SLN procedure had signiﬁcant less treat-
ment related morbidity and less worsening of quality of life compared
to those who underwent axillary lymph node dissection [19]. Our
study in 62 patients therefore is probably underpowered to detect
small differences in global quality of life.
In general data on quality of life in vulvar cancer patients are limited.
The main focus of the studies available on vulvar cancer and
psychosocial well-being/quality of life is sexual functioning; this
domain of quality of life appears to be signiﬁcantly reduced in vulvar
cancer patients 20–24]. Apart from our present study the only other
study on vulvar cancer and global quality of lifewas performed by Janda
et al. They developed a vulvar cancer-speciﬁc quality of life subscale to
accompany the Functional Assessment of Cancer-General (FACT-G)
questionnaire. Reductions in emotional functioning, physical function-
ing, social functioning, sexuality and body image were observed in
vulvar cancer patients [25]. In our study, no differences were observed
in sexual functioning or sexual activeness between SLN only and full
lymphadenectomy patients, which can be explained by the fact that
sexual activeness is mainly inﬂuenced by the vulvar surgery, whichwas
the same in both groups. Likes et al showed that sexual functioning and
overall quality of life were reduced after vulvar excision without groin
surgery in patients with vulvar intraepithelial neoplasia [26]. In
comparison to healthywomen sexual activitywas low inour population
with only 11/62women being sexually active (mean age: 57 years). It is
well-known that the prevalence of sexual activity in healthy women
declines with age: 62% of women between 57 and 64 years, 40%
between 65 and 74 years and 17% between 75 and 85 years [27].
We compared the results of the EORTC QLQ-C30 questionnaire in
our study to the results of two studies in a general (healthy)
population of women aged ≥60 years. This indicated that the overall
quality of life in our study population is comparable to a general age-
matched population [28,29]. A study by Miller et al., comparing
healthy patients with those who survived a gynecologic malignancy
(51 cervical cancers, 24 uterine cancer and 10 ovarian cancers)
showed that there were no overall differences in quality of life [30].
During follow-up after treatment for gynecological cancer an
improvement on all quality of life scales was observed [31].Apparently, the overall recovery from treatment for gynecological
cancer is good. Also for other minimal invasive techniques, such as
laparascopic hysterectomy, it was observed that after recovery from
primary treatment, no differences were found in quality of life when
compared to abdominal hysterectomy. The advantages for less
invasive surgery were only signiﬁcant in the ﬁrst 6 weeks after
treatment [32]. Surviving cancer might also coincide with attitudinal
changes. Cancer patients report that the cancer experience changed
them in many ways, that it enriched them, deepened the compassion
that they felt for others and energized them to look for changes in
their environment and the future [33]. These effects of cancer can not
be ignored when talking about quality of life issues. Important in this
context is the concept of “response shift”. Cancer and its treatment
changes patients' internal standards, values and/or the conceptuali-
zation of health related quality of life. These changes are inherent to
the process of accommodating to the illness [34].
Finally, a previous study from our group indicated that most vulvar
cancer patients treated by inguinofemoral lymphadenectomy would
not recommend the SLN procedure to relatives in light of different
hypothesized false-negative rates [12]. In the present study, we found
high percentages of acceptance, even when 10 out of 100 metastases
would be missed. Patients who had a metastatic SLN and therefore
underwent a full lymphadenectomy were less likely to advise a new
method if there was a chance of missing metastases. These patients
are likely more willing to accept and live with complications knowing
they needed this more extensive approach and would therefore be
less willing to trust a new procedure that could potentially under-
estimate the extent of their disease, not realizing that in fact it reliably
revealed their indication for inguinofemoral lymphadenectomy. Also,
they themselves did not experience the beneﬁts of being treated by
the new technique and this puts the low acceptance rate in our ﬁrst
study from our ﬁrst study in a different perspective. In that study all
patients underwent a full lymphadenectomy, which apparently
inﬂuenced their appreciation of the SLN procedure.
In conclusion, our quality of life study bymeans of the EORTC-QLQ-
C30 and a vulvar speciﬁc questionnaire shows that patients who
underwent a SLN procedure alone report less treatment related
morbidity compared to patients who underwent inguinofemoral
lymphadenectomy, but this did not inﬂuence overall quality of life.
Patients who underwent the SLN procedure without inguinofemoral
lymphadenectomy were more content with the procedure they
underwent and were more likely to advise new treatment options to
relatives, probably because they themselves experienced the beneﬁts
of a new procedure. Our data should be helpful for health
professionals when counseling vulvar cancer patients on the pros
and cons of a SLN procedure in early stage vulvar cancer.
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